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Abstract
Background: The precise mechanism linking systemic inflammation with insulin resistance (IR) in rheumatoid arthritis
(RA) remains elusive. In the present study, we determined whether the incretin-insulin axis and incretin effect are
disrupted in patients with RA and if they are related to the IR found in these patients.
Methods: We conducted a cross-sectional study that encompassed 361 subjects without diabetes, 151 patients with RA,
and 210 sex-matched control subjects. Insulin, C-peptide, glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide
(GIP), dipeptidyl peptidase 4 (DPP-4) soluble form, and IR indexes by homeostatic model assessment (HOMA2) were
assessed. A multivariable analysis adjusted for IR-related factors was performed. Additionally, ten patients and ten control
subjects underwent a 566-kcal meal test so that we could further study the postprandial differences of these molecules
between patients and control subjects.
Results: Insulin, C-peptide, and HOMA2-IR indexes were higher in patients than in control subjects. This was also the case
for GLP-1 (0.49 ± 1.28 vs. 0.71 ± 0.22 ng/ml, p = 0.000) and GIP (0.37 ± 0.40 vs. 1.78 ± 0.51 ng/ml, p = 0.000). These
differences remained significant after multivariable adjustment including glucocorticoid intake. Disease Activity
Score in 28 joints with erythrocyte sedimentation rate (β coefficient 46, 95% CI 6–87, p = 0.026) and Clinical Disease
Activity Index (β coefficient 7.74, 95% CI 1.29–14.20, p = 0.019) were associated with DPP-4 serum levels. GLP-1 positively
correlated with β-cell function (HOMA2 of β-cell production calculated with C-peptide) in patients but not in control
subjects (interaction p = 0.003). The meal test in patients with RA revealed a higher total and late response AUC
for glucose response, a later maximal response of C-peptide, and a flatter curve in GIP response.
Conclusions: The incretin-insulin axis, both during fasting and postprandial, is impaired in patients with RA.
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Background
The concept that oral nutrient (glucose) administration
promotes a much greater degree of insulin secretion
than a parenteral isoglycemic glucose infusion underlies
the incretin effect, namely the existence of gut-derived
factors that enhance glucose-stimulated insulin secretion
from the islet β cell. This phenomenon is estimated to
account for approximately 50–70% of the total insulin
secreted following oral glucose administration. To date,
gastric inhibitory polypeptide (GIP) [1] and glucagon-
like peptide-1 (GLP-1) [2] fulfill the definition of an
incretin hormone in humans.
Furthermore, several studies have shown that these
two peptides potentiate glucose-stimulated insulin secre-
tion in an additive manner, likely contributing equally to
the incretin effect and together fully accounting for most
of the incretin effect in humans. GIP and GLP-1 are de-
graded by dipeptidyl peptidase 4 (DPP-4) [3], which is a
membrane-associated peptidase widely distributed
throughout numerous tissues. DPP-4 also exists as a
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soluble circulating form in plasma, and significant DPP-
4-like activity is detectable in plasma from humans. Sev-
eral studies have confirmed that DPP-4-mediated inacti-
vation of these peptides is a critical control mechanism
for regulating the biological activity of both GIP and
GLP-1 in vivo in humans [4]. This arc of discovery has
led to newly approved antidiabetic therapies during the
last decade: GLP1 analogues (exenatide, liraglutide) and
DPP-4 inhibitors (saxagliptin, sitagliptin, vildagliptin).
Additionally, there has been considerable interest in de-
termining whether insulin resistance (IR) and diabetes
are associated with one or more defects in this incretin
axis, as well as whether these defects contribute to the
development of type 2 diabetes or arise as a conse-
quence of hyperglycemia or other metabolic manifesta-
tions of diabetes itself.
Several studies have shown an increased prevalence of
IR in patients with rheumatoid arthritis (RA) [5–7], a
finding potentially associated with the degree of RA dis-
ease activity [8]. It is thought that low-grade inflamma-
tion may contribute to its development [9]. This is
supported by the fact that IR in patients with RA has
been found to directly correlate with levels of interleukin
6, tumor necrosis factor (TNF)-α, and C-reactive protein
(CRP) [10]. In addition, anti-TNF-α therapy has been
shown to improve insulin sensitivity and reduce IR in
RA [11]. However, the precise mechanism linking sys-
temic inflammation with IR in RA remains elusive. In
the present study, we sought to determine whether the
incretin-insulin axis and incretin effect are impaired in
patients with RA, as well as if they are related to the IR
found in these patients.
Methods
Study participants
We conducted a cross-sectional study that included 361
nondiabetic individuals. Of these, 151 were nondiabetic
patients with RA and 210 were sex-matched control
subjects. All patients with RA were aged 18 years or
older and fulfilled the 2010 American College of
Rheumatology/European League Against Rheumatism
classification criteria for RA [12]. They had been diag-
nosed by rheumatologists and were periodically followed
at rheumatology outpatient clinics. For the purpose of
inclusion in the present study, RA disease duration was
required to be ≥ 1 year. Although anti-TNF-α treatment
has been associated with changes in IR [5, 13–15], pa-
tients with RA undergoing TNF-α antagonist therapy
were not excluded in the present study. The control
group consisted of patients recruited from the Spanish
Camargo Cohort [16, 17]. This cohort was set up be-
tween February 2006 and February 2011, and individuals
included in this cohort have been followed ever since.
The aim of using this cohort was to evaluate the
prevalence and incidence of metabolic bone diseases and
mineral metabolism disorders. Control subjects included
in the present study were subjects without diabetes.
Patients and control subjects with diabetes mellitus
were not included in the study. Therefore, none of the
patients or control subjects were receiving glucose-
lowering drugs or insulin therapy. All patients and con-
trol subjects had a glycemia < 7 mmol/L. Patients and
control subjects were excluded if they had a history of
cardiovascular events that included myocardial infarc-
tion, angina, stroke, or peripheral arteriopathy; a glom-
erular filtration rate < 60 ml/minute/1.73 m2; history of
cancer; or any other chronic disease or evidence of in-
fection. None of the control subjects were receiving
glucocorticoid treatment. However, because prednisone
is often used in the management of RA, patients taking
this drug or an equivalent dose ≤ 10 mg/day were not ex-
cluded. The study protocol was approved by the institu-
tional review committee at Hospital Universitario de
Canarias and Hospital Universitario Marqués de Valde-
cilla (both in Spain), and all subjects provided written in-
formed consent.
Data collection
Surveys of patients with RA and control subjects were
performed in the same way. Subjects completed a car-
diovascular risk factor and medication use questionnaire
and underwent a physical examination to determine
their anthropometrics and blood pressure. Medical re-
cords were reviewed to ascertain specific diagnoses and
medications. Waist circumference was measured at the
smallest circumference point between the rib cage and
the iliac crest while the subject was in a standing pos-
ition. The hip circumference was measured at the widest
circumference point between the waist and thighs. The
waist-to-hip ratio also was estimated. Hypertension was
defined as a systolic or diastolic blood pressure higher
than 140 or 90 mmHg, respectively. Dyslipidemia was
defined as one of the following metrics being present:
total cholesterol > 200 mg/dl, triglyceride > 150 mg/dl,
high-density lipoprotein (HDL) cholesterol < 40 mg/dl in
men or < 50 mg/dl in women, or low-density lipoprotein
(LDL) cholesterol > 130 mg/dl. In patients with RA, dis-
ease activity was measured using the Disease Activity
Score in 28 joints (DAS28) [18], and disease disability
was determined using the Health Assessment Question-
naire [19]. Clinical Disease Activity Index (CDAI) [20]
and Simplified Disease Activity Index (SDAI) [21] scores
for RA disease activity were obtained as previously
described.
Assessments
The homeostatic model assessment (HOMA) method
was performed to determine IR; specifically, in this
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study, we used HOMA2: the updated computer HOMA
model [22, 23]. Briefly, this method consists of a struc-
tural computer model of the glucose-insulin feedback
system in a homeostatic (overnight-fasted) state. The
model is composed of a number of nonlinear empirical
equations (and precludes an exact algebraic solution)
that describe the functions of organs and tissues in-
volved in glucose regulation. This model can be used to
determine insulin sensitivity (%S) and β-cell function
(%B) from paired fasting plasma glucose and specific in-
sulin or from C-peptide concentrations across a range of
1–2200 pmol/L for insulin and 1–25 mmol/L for glu-
cose. In our study, we used C-peptide to calculate β-cell
function because the former is a marker of secretion. In
addition, we used insulin data to calculate %S (because
HOMA-%S is derived from glucose disposal as a func-
tion of insulin concentration). This computer model
provides an insulin sensitivity value expressed as
HOMA2-%S (where 100% is normal). HOMA2-IR (IR
index) is simply the reciprocal of %S.
Insulin (ARCHITECT i2000; Abbott Diagnostics, Ab-
bott Park, IL, USA) and C-peptide (IMMULITE 2000;
Siemens Healthcare, Erlangen, Germany) were deter-
mined using chemiluminescent immunometric assays.
GLP-1 and GIP were assessed using an enzyme-linked
immunosorbent assay (ELISA) (Phoenix Pharmaceuti-
cals, Burlingame, CA, USA). The assay sensitivity (mini-
mum detectable concentration) was 0.11 ng/ml for GLP-
1 and 0.47 ng/ml for GIP. These two ELISAs do not
cross-react with human insulin, and the presence of in-
sulin in serum does not interfere with the assay results.
The kits also have no cross-reactivity with the major
species of proinsulin metabolites. The GLP-1 assay does
not have cross-reactivity with human GLP-2 or human
glucagon. Similarly, the GIP kit does not cross-react with
human amylin. Precision was estimated for GLP-1 as
interassay 3.79–3.85 and intra-assay 3.81%, for GIP as
interassay 3.7–5.06 and intra-assay 4.40%. Serum levels
of soluble CD26/DPP-4 were measured through ELISA
(R&D Systems, Inc., Minneapolis, MN, USA). The intra-
assay and interassay coefficients of variation were 4.2%
and 8.1%, respectively. Standard techniques were used to
measure plasma glucose, CRP, the Westergren erythro-
cyte sedimentation rate (ESR), and serum lipids. Blood
collected from all the participants by means of
venipuncture was stored at 4 °C for < 4 h and then cen-
trifuged, and subsequently serum/plasma was removed
and stored at −80 °C.
Meal test
Ten nondiabetic patients with RA (mean age 45 ± 8 years,
body mass index [BMI] 22.6 ± 4.1 kg/m2) and ten control
subjects (mean age 46 ± 10 years, BMI 26.6 ± 5.2 kg/m2)
were tested for postprandial levels of glucose, insulin, C-
peptide, GIP, and GLP-1 after a meal test. For the purpose
of this study, both patients and control subjects must have
had a BMI < 30 kg/m2. In addition, patients with RA were
selected if disease activity was not considered to be in re-
mission (DAS28 ≥ 2.6). In order to avoid the confusing ef-
fect it could have, none of the patients with RA were on
glucocorticoid therapy. Additional file 1: Table S1 de-
scribes the demographic and disease-related characteris-
tics of these 20 subjects in whom the meal test was
performed. The test meal consisted of 50 g of white bread,
50 g of black bread, 10 g of butter, 40 g of cheese, 20 g of
jam, and 200 ml of milk (34% fat, 47% carbohydrate, and
19% protein), comprising a total of 566 kcal (2370 kJ), and
the meal was consumed within 15 minutes. Venous blood
was drawn 10 minutes before and 30, 60, 90, 120, 150,
180, 210, and 240 minutes after ingestion of the meal.
Blood samples were placed in tubes that were immediately
cooled on ice and centrifuged within 20 minutes at 4 °C,
and plasma was stored at −20 °C until prompt analysis.
Statistical analysis
Demographic and clinical characteristics were compared be-
tween patients with RA and control subjects using the chi-
square test for categorical variables or Student’s t test for
continuous variables (with data described as mean ± SD).
For noncontinuous variables, either the Mann-Whitney U
test was performed or logarithmic transformation was done,
and data were expressed as median and IQR. Binary vari-
ables included in Additional file 1: Table S1 were compared
using Fisher’s exact test. Differences in glucose homeostasis
metabolism molecules and HOMA indexes were studied
using three different linear multivariable regression models:
a univariate unadjusted model; a second model adjusted for
those variable with a p value < 0.20 in the differences be-
tween patients and control subjects (age, sex, waist circum-
ference, dyslipidemia, statins, antihypertensive treatment,
and CRP and cholesterol levels); and a third model with the
same variables, though with the addition of glucocorticoid
intake as a binary variable. The association of incretins and
DPP-4 with HOMA2 indexes was assessed with multivari-
able regression analysis performed with the predictive data
of the adjusted model (for age, sex, waist circumference, dys-
lipidemia, statins, antihypertensive treatment, CRP and chol-
esterol levels, and glucocorticoid intake). Differences
between control subjects and patients in the β coefficients of
the relationship between incretins (independent variable)
and HOMA2 IR indexes (dependent variable) were assessed
by adding incretins × RA as an interaction factor into the
linear regression models. For the meal test, early response
from baseline to minute 60, late response from minute 60 to
minute 240, maximum response (expressed in the molecule
units as median and IQR) and minutes to maximum re-
sponse were defined. Differences between AUC in the meal
test were calculated using the DeLong method [24]. For all
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analyses, we used a 5% two-sided significance level, and all
analyses were performed using IBM SPSS Statistics ver-
sion 21 software (IBM, Armonk, NY, USA) and Stata
version 13/SE software (StataCorp, College Station, TX,
USA). A p value < 0.05 was considered statistically
significant.
Results
Demographic, analytical, and disease-related data
A total of 361 nondiabetic participants comprising
151 patients with RA, and 210 control subjects with
mean ± SD ages of 53 ± 11 years and 58 ± 9 years (p =
0.00), respectively, were included in this study. The
demographic and disease-related characteristics of the
participants are shown in Table 1. There were no dif-
ferences between patients and control subjects regard-
ing BMI, although waist circumference was found to
be higher in patients than in control subjects (92 ± 14
vs. 96 ± 13 cm, p = 0.015). The frequency of hyperten-
sion was not different between patients and control
subjects. This was not the case for the lipid profile.
In this regard, patients with RA had lower levels of
total cholesterol (206 ± 36 vs. 219 ± 37 mg/dl, p =
0.000), LDL cholesterol (121 ± 31 vs. 135 ± 34 mg/dl,
p = 0.000), HDL cholesterol (56 ± 15 vs. 63 ± 18 mg/dl,
p = 0.000), and apolipoprotein A1 (170 ± 28 vs. 191 ±
35 mg/dl, p = 0.000). In contrast, triglycerides, lipo-
protein A, and apolipoprotein B were found to be
higher in patients with RA.
As expected, the assessment of ESR and CRP values
revealed statistically significant higher levels in pa-
tients with RA. Patients from our series had moderate
active disease as shown by DAS28 (3.7 ± 1.2), and 50
(38%) of them were on prednisone (median dose 5
[IQR 5–6] mg/day). Disease duration was 6.6 (IQR
3.3–13.9) years, and 59% and 72% were positive for
anticitrullinated protein antibodies and rheumatoid
factor, respectively. In addition, whereas 85% of the
patients were on disease-modifying antirheumatic
drugs, 13% were on anti TNF-α treatment and 23%
were receiving biologic therapy.
Differences in carbohydrate metabolism molecules,
incretins, and insulin resistance indexes between patients
with RA and control subjects
HOMA2-IR indexes, whether calculated with insulin
or C-peptide, were different between patients and con-
trol subjects (Table 2). In this sense, HOMA2-S% was
lower in patients with RA than in control subjects
after adjusting for traditional IR-related factors and
prednisone intake (105 ± 53 vs. 108 ± 75, p = 0.006).
Similarly, HOMA2-IR was found to be higher in pa-
tients with RA than in control subjects after multivari-
able analysis (1.27 ± 0.82 vs. 1.65 ± 1.69, p = 0.054). In
contrast, HOMA2-%B was higher in patients with RA
in the univariate analysis. However, the difference was
lost after adjustment for covariables (p = 0.14).
When HOMA2 indexes were constructed with C-
peptide, the differences between patients and control
subjects were found to be stronger. In this regard,
all comparisons disclosed higher HOMA2-IR and
HOMA2-%B indexes and lower HOMA2-%S in pa-
tients with RA even after multivariable analysis
(Table 2).
Whereas glucose serum levels were not different be-
tween control subjects and patients, insulin (9.8 ± 6.5
vs. 13.0 ± 13.4 U/ml, p = 0.007) and C-peptide serum
levels (1.53 ± 0.77 vs. 3.37 ± 2.94 ng/ml, p = 0.000)
were found to be upregulated in patients with RA.
These differences were maintained after multivariable
adjustment including glucocorticoid intake. Similarly,
GLP-1 (0.49 ± 1.28 vs. 0.71 ± 0.22 ng/ml, p = 0.06 in
univariate analysis) and GIP (0.37 ± 0.40 vs. 1.78 ±
0.51 ng/ml, p = 0.000) were higher in patients with
RA than in control subjects. These differences were
also present after adjusting for factors related to IR
and prednisone intake; in the case of GLP-1, it
reached statistical significance (p = 0.000) after multi-
variable analysis. In contrast, DPP-4 soluble-form
serum levels were found to be significantly lower in
patients with RA than in control subjects (811 ± 459
vs. 696 ± 301 ng/ml) in univariate analysis. These dif-
ferences were out of the range of significance after
adjustment (p = 0.15) (Table 2).
Laboratory markers of inflammation, disease-related data,
and disease activity relationship vis-à-vis incretins, DPP-4,
and HOMA-IR indexes
Regarding inflammatory serum markers, CRP and ESR
showed a significant positive correlation with HOMA2-
%B and GIP, respectively (β coefficient [95% CI 0.01
[0.00–0.01] ng/ml, p = 0.033]. Although disease duration
and rheumatoid factor were not related to carbohydrate
metabolism molecules, the presence of anticitrullinated
peptide/protein antibody was negatively associated with
insulin and C-peptide serum levels and HOMA2-%B, but
it was positively correlated with DDP-4 levels (β coeffi-
cient 157 [95% CI 58–256] ng/ml, p = 0.002). Disease ac-
tivity scores through DAS28-ESR (β coefficient 46 [95%
CI 6–87], p = 0.026) and CDAI (β coefficient 7.74 [95% CI
1.29–14.20] 0.019) were positively associated with DPP-4
serum levels but not with other molecules or HOMA-IR
indexes (Table 3). Furthermore, disease activity stratifica-
tion did not yield any additional associations.
With regard to RA treatments, neither methotrexate
nor anti-TNF-α inhibitors were related to insulin, incre-
tins, DPP-4 serum levels, or IR indexes. In contrast, glu-
cocorticoids were significantly associated with higher
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Table 1 Demographics, analytical data, and disease-related characteristics of patients with rheumatoid arthritis and control subjects
Control subjects (n = 210) Patients with RA (n = 151) p Value
Age, years 58 ± 9 53 ± 11 0.000
Female sex, n (%) 148 (70) 120 (79) 0.052
Body mass index, kg/m2 28 ± 5 28 ± 5 0.78
Waist circumference, cm 92 ± 14 96 ± 13 0.015
Cardiovascular risk factors, n (%)
Smoking 42 (20) 26 (17) 0.51
Hypertension 58 (27) 45 (30) 0.65
Dyslipidemia 33 (15) 54 (36) 0.000
Diabetes 0 (0) 0 (0) –
Medication
Statins 14 (6) 43 (28) 0.000
Antihypertensive treatment 35 (16) 45 (30) 0.003
Analytical data
CRP, mg/dl 1.0 (1.0–3.0) 3.2 (1.5–5.8) 0.000
ESR, mm/h 10 ± 8 34 ± 22 0.000
Triglycerides, mg/dl 104 ± 50 144 ± 92 0.000
HDL cholesterol, mg/dl 63 ± 18 56 ± 15 0.000
LDL cholesterol, mg/dl 135 ± 34 121 ± 31 0.000
Total cholesterol, mg/dl 219 ± 37 206 ± 36 0.001
Lipoprotein A, mg/dl 16 (9–39) 35 (11–121) 0.000
Apolipoprotein A1, mg/dl 191 ± 35 170 ± 28 0.000
Apolipoprotein B, mg/dl 102 ± 24 110 ± 63 0.11
ApoB/ApoA ratio 0.55 ± 0.16 0.66 ± 0.30 0.000
Atherogenic index 3.7 ± 4.0 4.0 ± 3.6 0.10
Disease-related data
Disease duration, years 6.6 (3.3–13.9)
ACPA, n (%) 89 (59)
Rheumatoid factor, n (%) 109 (72)
Erosions, n (%) 55 (36)
Extra-articular manifestations, n (%) 16 (11)
DAS28-ESR 3.7 ± 1.2




Current prednisone, n (%) 57 (38)
Prednisone current doses, mg/day 5 (5–6)
NSAIDs, n (%) 69 (46)
DMARDs, n (%) 129 (85)
Methotrexate, n (%) 113 (75)
Biologic drugs, n (%) 35 (23)
Anti-TNF-α drugs, n (%) 20 (13)
Abbreviations: ACPA Anticitrullinated peptide/protein antibody, Apo Apolipoprotein, BMI Body mass index, CDAI Clinical Disease Activity Index, CRP C-reactive
protein, DAS28 Disease Activity Score in 28 joints, DMARD Disease-modifying antirheumatic drug, ESR Erythrocyte sedimentation rate, HAQ Health Assessment
Questionnaire, HDL High-density lipoprotein, LDL Low-density lipoprotein, NSAID Nonsteroidal anti-inflammatory drug, RA Rheumatoid arthritis, SDAI Simplified
Disease Activity Index, TNF-α Tumor necrosis factor-α
Current prednisone doses pertain to prednisone users only. Data are expressed as mean ± SD or median (IQR). Dichotomous variables are expressed as
count and percent. p<0.05 are depicted in bold
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levels of insulin, C-peptide, GLP-1, GIP, and HOMA-IR
indexes, as well as with lower levels of DPP-4 (Table 3).
Relation of incretins and DPP-4 to IR indexes
DPP-4 serum levels showed a correlation with IR
(HOMA2-IR) and β-cell secretion (HOMA2-%B-C-pep-
tide) in both patients and control subjects after multi-
variate regression analysis. In both cases, they had a
negative and statistically significant correlation with both
indexes. A β-coefficient comparison revealed no differ-
ences, showing that the relationship of DPP-4 to these
indexes, whether in patients or in control subjects, did
not differ (Table 4).
GIP had a statistically significant association with
HOMA2-%B-C-peptide in both patients and control
subjects, which did not differ between the two popula-
tions (interaction p = 0.29). Otherwise, GIP was found to
be related to HOMA2-IR in patients with RA but not in
control subjects, although the interaction factor in this
case was not significant. Regarding GLP-1, its relation-
ship to HOMA-IR (interaction p = 0.068) and
HOMA2%-C-peptide (interaction p = 0.003) was differ-
ent between patients and control subjects. In fact, al-
though the relationship of GLP-1 to HOMA-IR was
found to be negative in control subjects (β coefficient
−1.34 [95% CI −2.46 to −0.23], p = 0.018), its correlation
with HOMA2-%B-C-peptide was found to be positive
and statistically significant in patients with RA (β coeffi-
cient 155 [95% CI 105–205], p = 0.000) (Table 4).
Meal test
Additional file 1: Table S1 shows the characteristics of
patients and control subjects who underwent the meal
test. Traditional cardiovascular risk factors, use of medi-
cations, and laboratory data did not differ between pa-
tients and control subjects. Only waist circumference
was found to be higher in patients with RA (75.3 ± 11.8
vs. 95.3 ± 10.0 cm, p = 0.028). Fasting GIP serum levels
were also higher in patients with RA than in control
subjects (0.93 ± 0.14 vs. 1.14 ± 0.18 ng/ml, p = 0.029).
The AUC of glucose response after the meal test was
found to be higher in patients with RA compared with
control subjects (691 ± 78 vs. 843 ± 114, p = 0.006). Late-
response AUC in glucose response was also higher in
patients with RA, although statistical significance was
not reached (p = 0.054). Similarly, C-peptide minutes
until maximal response was higher in patients with RA
compared with control subjects (30 [30-60] vs. 75 [60-
105] minutes, p = 0.029). Although an insulin AUC com-
parison between patients and control subjects showed
no differences, visually AUC was higher in patients with
RA and slower than in control subjects. Moreover, GIP
response had a flatter curve in patients with RA, al-
though statistical significance was not reached in this
case (Table 5 and Fig. 1).
Discussion
The present study shows, for the first time, to our know-
ledge, the expression of incretins in patients with RA.
According to our findings, incretins and DPP-4 differ in
Table 2 Linear regression analysis of differences in carbohydrate metabolism molecules, incretin hormones, and insulin resistance
indexes between patients with rheumatoid arthritis and control subjects
Univariate model Adjusted model Adjusted model + GC
Control subjects (n = 210) Patients with RA (n = 151) p Value β Coefficient (95% CI) p Value β Coefficient (95% CI) p Value
Glucose, mg/dl 90 ± 10 88 ± 19 0.21 3 (−1 to 7) 0.37 1 (−4 to 5) 0.71
Insulin, U/ml 9.8 ± 6.5 13.0 ± 13.4 0.007 3.0 (0.2 to 5.8) 0.037 3.2 (0.1 to 6.4) 0.046
C-peptide, ng/ml 1.53 ± 0.77 3.37 ± 2.94 0.000 2.13 (1.56 to 2.69) 0.000 1.98 (1.35 to 2.61) 0.000
GLP-1, ng/ml 0.49 ± 1.28 0.71 ± 0.22 0.06 0.31 (0.25 to 0.38) 0.000 0.32 (0.25 to 0.39) 0.000
GIP, ng/ml 0.37 ± 0.40 1.78 ± 0.51 0.000 1.35 (1.19 to 1.51) 0.000 1.33 (1.15 to 1.51) 0.000
DPP-4, ng/ml 811 ± 459 696 ± 301 0.007 −112 (−213 to −10) 0.032 −85 (−199 to 30) 0.15
HOMA2 insulin
HOMA2-IR 1.27 ± 0.82 1.65 ± 1.69 0.011 0.38 (0.03 to 0.74) 0.036 0.39 (−0.01 to 0.79) 0.054
HOMA2-%S 108 ± 75 105 ± 53 0.65 −19 (3 to −35) 0.019 −25 (−7 to −42) 0.006
HOMA2-%B 111 ± 45 134 ± 69 0.000 8 (−8 to 23) 0.33 13 (−4 to 31) 0.14
HOMA2 C-peptide
HOMA2-IR 1.13 ± 0.58 2.49 ± 2.35 0.000 1.63 (−1.18 to 2.09) 0.000 1.51 (1.00 to 2.02) 0.000
HOMA2-%S 115 ± 75 67 ± 41 0.000 −51 (−68 to −34) 0.000 −45 (−64 to −28) 0.000
HOMA2-%B 104 ± 36 180 ± 82 0.000 71 (55 to 88) 0.000 74 (55 to 93) 0.000
Abbreviations: DPP-4 Dipeptidyl peptidase 4, GC Glucocorticoid, GIP Gastric inhibitory polypeptide, GLP-1 Glucagon-like peptide 1, HOMA Homeostatic model
assessment, HOMA2-%B Homeostatic model assessment of β-cell production calculated with C-peptide, HOMA2-IR Homeostatic model assessment calculated
with insulin, RA Rheumatoid arthritis
Adjusted model for age, sex, waist circumference, dyslipidemia, statins, antihypertensive treatment, and C-reactive protein and cholesterol levels. Analytical
data represent unadjusted values: β coefficient (95% CI). p<0.05 are depicted in bold
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patients with RA and control subjects. This is related to
disease activity and glucocorticoid intake. We also ob-
served that insulin, C-peptide levels, and HOMA-IR in-
dexes are independently elevated in patients with RA
compared with control subjects.
We have previously demonstrated that β-cell function
is impaired in patients with RA because of the elevation
in serum levels of split and intact forms of proinsulin
[7]. In keeping with former studies [8, 25, 26], our data
confirmed the association between IR and RA. In this
context, Chung et al. studied IR in 104 patients with RA
and 124 patients with systemic lupus erythematosus
(SLE). The former had a higher IR index than those with
SLE, and IR showed a positive correlation with the levels
of proinflammatory cytokines interleukin-6, TNF-α, and
CRP [27]. Severe IR has been also found to be present in
patients with early untreated RA [28].
Type 2 diabetes mellitus was thought to be character-
ized by a severely impaired or absent GIP insulinotropic
effect that most likely resulted in worsening insulin se-
cretion. However, current analyses have revealed that
type 2 diabetes seems unlikely to result from deficient
incretin secretion [29]. On the basis of results obtained
during the course of both oral glucose tolerance testing
and meal testing, GIP secretion and fasting levels actu-
ally seem to increase in both the impaired and diabetic
state [30]. In our study, fasting incretin serum levels
were higher in patients with RA than in control subjects.
Table 4 Multivariable analysis of relationship of incretins and dipeptidyl peptidase 4 with insulin resistance indexes
β Coefficient (95% CI) β Coefficient (95% CI)
HOMA-IR p Value p Value* HOMA2%B-C-peptide p Value p Value*
GLP-1, ng/ml
Patients with RA 0.00 (−0.93 to 0.93) 0.99 0.068 155 (105 to 205) 0.000 0.003
Control subjects −1.34 (−2.46 to −0.23) 0.018 37 (−22 to 96) 0.22
GIP, ng/ml
Patients with RA 0.32 (0.10 to 0.53) 0.004 0.42 59 (50 to 68) 0.000 0.29
Control subjects 0.14 (−0.22 to 0.51) 0.44 49 (31 to 66) 0.000
DPP-4, ng/ml
Patients with RA −0.002 (−0.003 to −0.002) 0.000 0.39 −0.12 (−0.16 to −0.09) 0.000 0.71
Control subjects −0.003 (−0.003 to −0.002) 0.000 −0.13 (−0.18 to 0.09) 0.000
Abbreviations: DPP-4 Dipeptidyl peptidase 4, GIP Gastric inhibitory polypeptide, GLP-1 Glucagon-like peptide 1, HOMA2-%B Homeostatic model assessment of β-cell
production calculated with C-peptide, HOMA2-IR Homeostatic model assessment calculated with insulin, RA Rheumatoid arthritis
All analyses were adjusted for age, sex, waist circumference, dyslipidemia, statins, antihypertensive treatment, and CPR and cholesterol levels. GLP-1, GIP and DPP-
4 are considered independent variables. β Coefficients of the relation of GLP-1, GIP and DPP-4 (independent variables) with HOMA2 indexes (dependent variables)
are disclosed. p Values are the linear regression adjusted p values of these associations. p* Value refers to the statistical significance of the interaction factor when
adding GLP-1 × RA, GIP × RA, and DPP-4 × RA as such interaction factors to the model. p<0.05 are depicted in bold
Table 5 Glucose, insulin, C peptide, GIP and GLP-1 concentrations after meal test in RA patients and controls
Glucose p Insulin p C peptide p GIP p GLP-1 p
Maximum response Controls 102 (96-141) 0.11 27.2 (11.2-44.8) 0.49 4.98 (2.99-6.03) 0.20 1.49 (1.22-2.08) 0.73 0.59 (0.24-0.61) 0.73
RA patients 134 (127-138) 26.8 (12.8-56.0) 5.85 (3.98-7.96) 1.48 (1.37-1.81) 0.48 (0.45-0.62)
Minutes to max.
response
Controls 30 (30-240) 0.39 30 (30-60) 0.36 30 (30-60) 0.029 150 (60-210) 0.08 60 (60-120) 0.34
RA patients 75 (45-90) 45 (30-105) 75 (60-105) 45 (15-135) 45 (30-105)
AUC Controls 691 ± 78 0.006 92 ± 52 0.87 21 ± 7 0.23 9 ± 2 0.69 3 ± 1 0.34
RA patients 843 ± 114 105 ± 84 35 ± 21 10 ± 2 3 ± 1
Early response AUC Controls 195 ± 39 0.34 39 ± 23 0.99 7 ± 2 0.87 2.2 ± 0.3 0.28 0.7 ± 0.4 0.78
RA patients 217 ± 21 38 ± 29 7 ± 2 2.6 ± 0.6 0.8 ± 0.3
Late response AUC Controls 411 ± 44 0.054 33 ± 24 0.37 11 ± 3 0.12 6.0 ± 1.0 0.61 1.7 ± 0.8 0.40
RA patients 507 ± 99 59 ± 48 23 ± 17 6.2 ± 1.2 2.0 ± 0.6
Data expressed as median (interquartile range)
AUC are depicted as average ± standard deviation
Early response refers to the AUC from baseline to minute 60
Late response refers to the AUC from minute 60 to minute 240
Maximum response is expressed in the molecules units median and interquartile range
Minutes to maximum response is expressed in median and interquartile range
GLP-1: Glucagon-Like Peptide 1; GIP: gastric inhibitory polypeptide
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This increase in incretin levels was in keeping with the
upregulation of insulin and C-peptide. In contrast, DPP-
4 was found to be downregulated in patients with RA.
We believe that DPP-4 downregulation is consistent
with the increase in incretins due to the accepted oppos-
ite relationship of incretins and DPP-4. Interestingly,
DPP-4 was also found to be positively related to disease
activity through DAS28-ESR and CDAI scores.
Previous reports have shown decreased enzymatic ac-
tivity and low DPP-4 serum levels in patients with RA
compared with those of healthy control subjects [31,
32]. However, an increase in the number of peripheral T
lymphocytes expressing DPP-4 has been reported in pa-
tients with active RA [33]. This apparent contradictory
result may explain the positive correlation of DPP-4 with
disease activity observed in our patients with RA. Of
note, a recent study involving 50 patients with RA re-
vealed a decrease in DPP-4 serum activity but not in
DPP-4/CD26 expression [34]. In another study involving
27 patients with RA, there was also an elevation in blood
plasma DPP-4 but a decrease of DPP-4/CD26 in periph-
eral blood mononuclear cells after clinical improvement
following treatment [35]. Taking these observations into
account, we feel that the number of peripheral T lym-
phocytes expressing DPP-4/CD26 is higher in the blood
of patients with active RA. In contrast, however, the en-
zymatic activity and serum levels of DPP-4/CD26 may
be lower in the sera of patients with RA than in those of
healthy control subjects.
Interestingly, prednisone intake was associated with
higher levels of incretins and lower levels of DPP-4.
To the best of our knowledge, there are no studies
focused on the effects of glucocorticoids over incre-
tins or DPP-4 in chronic diseases. We believe that
the mechanism by which glucocorticoids impair
incretin may be similar to that underlying increases
in insulin and C-peptide: The glucose homeostasis
disruption and IR state that they induce probably lead
to a secondary and compensatory elevation in incre-
tins, as occurs with insulin and C-peptide.
We also assessed whether the relationships of incretins
and DPP-4 with insulin resistance (HOMA2-IR) and β-
cell function (HOMA2-%B-C-peptide) in patients with
RA differed from those in control subjects. Interestingly,
we observed a different relationship of HOMA indexes
with GLP-1 but not with GIP or DPP-4. It is known that
GIP does not modulate glucose-dependent insulin secre-
tion in type 2 diabetes, even at supraphysiological
(pharmacological) plasma levels. Therefore, GIP incom-
petence is detrimental to β-cell function, especially after
eating. GLP-1 remains insulinotropic in type 2 diabetes,
and this fact has led to the development of compounds
that activate the GLP-1 receptor with a view to improv-
ing insulin secretion [30]. In our study, we found that
GLP-1 was negatively related to HOMA-IR in control
subjects but not in patients with RA. In contrast, GLP-1
was positively related to β-cell function (HOMA2-%B-C-
peptide) in patients with RA but not in control subjects.
We do not have an explanation for this finding. We be-
lieve that although the association of GLP-1 with IR can
be lost in RA, it could still remain as an insulinotropic
agent in terms of enhancing higher β-cell secretion in
these patients.
We also focused on studying incretins in a nonfasting
(postprandial) state. To this end, we performed a meal
test in nonobese control subjects and patients who were
not taking glucocorticoids and who had moderate or
high disease activity. Reports regarding meal tests in
other populations, such as subjects with diabetes, used
similar numbers of individuals to those of our study [36]
because the meal test is technically complex and re-
quires a well-trained team. We feel that our results may
indicate that the meal test is different in patients with
RA when compared with control subjects and that the
expression of incretins after this meal test is altered in
patients with RA. In this regard, in patients with RA,
glucose, insulin, and GLP-1 curves were abnormal com-
pared with those of control subjects. With respect to the
trends observed in the meal test, we think that the as-
sessment of a larger series of patients and control
Fig. 1 Meal test curves of glucose, insulin, C-peptide, gastric inhibitory polypeptide, and glucagon-like peptide 1 concentrations in patients with
rheumatoid arthritis and control subjects
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subjects could have led to stronger results in terms of
statistical significance. Nevertheless, to the best of our
knowledge, such findings regarding the meal test in pa-
tients with RA have not previously been reported in the
literature.
Conclusions
Our study, which, to our knowledge, constitutes the first
assessment of the incretin-insulin axis and the incretin ef-
fect in RA, shows that these molecules (metabolic hor-
mones) are impaired in patients with RA. The presence of
this impairment reinforces the concept that the disease
itself, probably by means of the effect of inflammation,
leads to an IR state. Our results demonstrate the existence
of a mechanism linking inflammation with IR that war-
rants further studies.
Additional file
Additional file 1: Table S1. Demographics, analytical data, and disease-
related characteristics of patients with RA and control subjects who
underwent the meal test. (DOC 64 kb)
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